These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28433474)

  • 21. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
    Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
    J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in refractory MuSK antibody myasthenia gravis.
    Thakre M; Inshasi J; Marashi M
    J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
    Lebrun C; Bourg V; Bresch S; Cohen M; Rosenthal-Allieri MA; Desnuelle C; Ticchioni M
    J Neuroimmunol; 2016 Sep; 298():79-81. PubMed ID: 27609279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
    Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
    [No Abstract]   [Full Text] [Related]  

  • 26. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
    Iorio R; Damato V; Alboini PE; Evoli A
    J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 29. Rituximab in refractory myasthenia gravis: Extended prospective study results.
    Beecher G; Anderson D; Siddiqi ZA
    Muscle Nerve; 2018 Sep; 58(3):452-455. PubMed ID: 29742795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 31. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
    Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
    Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.
    Sachdeva J; Mahesh KV; Shree R; Jain G; Kapila AT; Shashikala TP; Goyal MK; Modi M; Lal V
    Indian J Pharmacol; 2020; 52(1):49-52. PubMed ID: 32201447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
    Burusnukul P; Brennan TD; Cupler EJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
    J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
    Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
    [No Abstract]   [Full Text] [Related]  

  • 38. Rituximab desensitization in two patients with muscle-specific kinase myasthenia gravis.
    Suh J; Slawski BR; Long AA; Guidon AC
    Muscle Nerve; 2019 Nov; 60(5):E35-E37. PubMed ID: 31469920
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.